Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn receives FDA approvable letter for ocular anesthetic drug
The approvable letter identified several minor CMC deficiencies that must be addressed and rectified before final approval is granted. The majority of these items have been addressed in
The approvable letter identified several minor CMC deficiencies that must be addressed and rectified before final approval is granted. The majority of these items have been addressed in
The AngioSculpt scoring balloon catheter multi-center coronary bifurcation study is a prospective, multi-center, single arm study evaluating the AngioSculpt as the primary treatment of the side-branch vessel along
CryoCath’s Arctic Front, which is used for the treatment of paroxysmal atrial fibrillation (PAF), is a unique cryoablation balloon catheter that allows physicians to safely and effectively isolate
This newly identified lead compound is the second from a program being evaluated as a potential treatment for respiratory disease. As a result of this identification, Pharmacopeia received
The study, a randomized double-blind, placebo-controlled, in-patient Phase I trial conducted in up to 64 adult volunteers, will examine the safety and immunogenicity of a single dose of
The CereTom is a portable eight slice CT scanner that acquires 1.25mm slices per rotation. According to NeuroLogica, CereTom is capable of performing NeCT, CT Perfusion, Xenon Perfusion
Under terms of this transaction, Novartis agreed to fully acquire Protez for $100 million. Protez’s owners are eligible for additional payments of up to $300 million, which are
Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in significant eyelash growth.
Data from the single-center, Phase I trial showed that bolus doses of NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT). Upon discontinuation of NU172
This transaction, which is subject to approval by Tercica stockholders holding a majority of the outstanding Tercica common stock, has been unanimously approved by Tercica’s board of directors